Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT procedures in France at CHU Rennes. The procedures were led by Professor Raphael Martins and his team, marking a significant milestone in the company's European expansion.
This development follows the recent CE Mark approval for LockeT, a device designed to improve procedural efficiency and patient outcomes after cardiac ablation procedures. CHU Rennes, which is also a commercial partner for VTAK's VIVO product line, represents the company's growing presence in the European medical device market.
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology products, has received notification for a new patent issuance from the U.S. Patent and Trademark Office. The patent, titled "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model," enhances the company's VIVO product line.
The new patent adds to Catheter Precision's existing IP portfolio for VIVO, which is designed to help physicians identify ventricular arrhythmias noninvasively before procedures. CEO David Jenkins emphasized the importance of patents and trademarks in their business strategy and their commitment to advancing medical technology for improved patient care.
Catheter Precision (NYSE:VTAK) has initiated enrollment in the LockeT Compare Study, with the first three patients already enrolled. This single-center, physician-initiated study aims to evaluate the safety profile of the LockeT suture retention device compared to internal closure devices.
The study will enroll up to 100 patients and focuses on addressing groin complications after cardiac catheter procedures. Previous clinical data for LockeT has demonstrated safety, effectiveness, and cost reduction benefits while maintaining existing hospital workflows. The device creates hemostasis externally and may potentially reduce thrombotic episodes compared to internal closure mechanisms.
Catheter Precision (NYSE:VTAK) has received regulatory approval for its LockeT suture retention device in the United Kingdom, following its CE Mark approval in May 2025. The company has partnered with HC21, a major UK-based distributor with €180 million in annual revenue and 500+ employees across the UK and Ireland.
The LockeT device is designed to enhance patient comfort, enable earlier discharge after cardiac procedures, and support NHS efforts to reduce waiting lists. The company will distribute the product through HC21's established network, leveraging their existing partnership to bring the innovative cardiac device to the UK healthcare market.
Catheter Precision (NYSE American: VTAK), a medical device company specializing in cardiac electrophysiology products, has implemented a 1-for-19 reverse stock split effective August 15, 2025. The split will reduce the company's outstanding common shares from 23,316,520 to approximately 1,657,640.
The stock will continue trading under the symbol "VTAK" with a new CUSIP number 74933X708. Proportional adjustments will be made to equity awards, warrants, and other convertible securities. No fractional shares will be issued; instead, stockholders entitled to fractional shares will receive pro-rata proceeds from their sale.
Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT cases in Germany at Zentralklinik Bad Berka, one of Thuringia's largest hospitals.
The medical team has successfully conducted 10 cases using LockeT to close single or multiple punctures with a single device per case. The procedures demonstrated LockeT's versatility by handling sheath sizes ranging from 6F to 17Fr. The company views Germany as a significant European market opportunity, particularly due to its price-conscious nature.
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology, reported significant growth in Q2 2025. Revenue surged 128% year-over-year to $212,000 and 48% sequentially. The company achieved several milestones, including receiving CE Mark for LockeT and completing strategic acquisitions.
Notable clinical achievements include successful trials demonstrating VIVO's 94% accuracy in non-invasive localization and 83% long-term procedural success. The company formed Kardionav, Inc. for developing implant-based software for ventricular tachyarrhythmia treatment. However, the company reported a net loss of $5.4 million for Q2 2025, with $3.2 million in non-cash charges, and maintained a cash position of $838,000.
Catheter Precision (NYSE:VTAK) announced that the Heart Hospital of New Mexico has achieved a significant milestone by completing 200 ventricular ablation procedures using the company's VIVO system. The Heart Hospital, part of the Lovelace Health system, is New Mexico's only hospital dedicated exclusively to cardiovascular care.
The Lovelace Health system encompasses five hospitals, 33 health care clinics, and seven outpatient therapy clinics with over 300 healthcare providers. The hospital's physician team has published data and facilitated educational initiatives for other physicians regarding the VIVO technology.
Catheter Precision (NYSE:VTAK) has secured its largest purchase order to date for its VIVO product line from Centre Hospitalier Universitaire (CHU) de Rennes in France. The hospital, which serves approximately 500,000 patients annually, performs over 150 ventricular ablations per year, making it one of Europe's largest ventricular ablation centers.
CEO David Jenkins emphasized the strategic importance of partnering with teaching hospitals to introduce their products to physicians early in their careers, which could lead to long-term product adoption.
Catheter Precision (NYSE:VTAK) has announced the formation of a new joint venture called Kardionav to develop advanced AI-powered software for ventricular tachycardia (VT) ablation. The venture combines VTAK's expertise with Chelak iECG to enhance VT treatment outcomes through improved mapping technology.
The ownership structure allocates 56% to VTAK, 33% to Chelak iECG, and 10% to management. Dr. Jie Cheng, founder of Chelak iECG and Clinical Professor at Baylor College of Medicine, will serve as the primary researcher, bringing significant AI and arrhythmia localization expertise to the venture.
The joint venture aims to develop a standalone ventricular mapping system that will integrate vector technology with imaging of conduction channels and velocity calculations. This next-generation technology builds upon VTAK's existing VIVO platform and seeks to address current limitations in VT ablation procedures, including lengthy procedure times and imprecise ablation site targeting.